Vegetarian diet
BehavioralOther names: lacto-ovo-vegetarian diet
NCT Number: NCT03194334
Balanced vegetarian diets are popular and contain health-promoting characteristics. A balanced lacto-ovo-vegetarian diet differs in nutrient intake from an omnivorous diet, e.g. by increased intake of fibre, magnesium and antioxidants, but lower intake of omega-3 fatty acids and vitamin B12. However, the impact of reduced to near absent intake of carnitine, carnosine and creatine in a vegetarian diet is less well established and could be relevant in relation to muscle function, exercise capacity and sports performance. Few longitudinal intervention studies investigating the effect of a vegetarian diet on the availability of these compounds currently exist.
This study aimed therefore to investigate the effect of of transiently switching omnivores onto a vegetarian diet for 6 months on muscle and plasma creatine, carnitine and carnosine homeostasis.
We hypothesized that homeostasis of creatine and carnosine would be disrupted when their dietary intake was missing. For carnitine, however, we hypothesized that homeostasis can be maintained given its slow turnover rate and its presence in some non-meat nutrients. A second aim was to investigate whether supplementation of creatine and beta-alanine (the rate-limiting precursor of carnosine synthesis), concurrently with a lacto-ovo-vegetarian diet, was able to correct for potentially emerging deficiencies.
Looking for future studies?
Notify Me18 year and older
Female
Interventional
Not applicable
Forty healthy female omnivores will be included in this 6-month intervention study. Exclusion criteria are smoking, chronic use of medication, athletes participating in competitions, vegetarianism or eating meat or fish less than 5 times a week. The study is scheduled over a period of 6 months and measurements will be performed 1 week prior to the intervention (0M), after 3 months (3M) and within the last week (6M). Ten women will continue their omnivorous diet throughout the entire study (controls) and the other 30 subjects will switch to a lacto-ovo-vegetarian diet for 6 months. The vegetarian group will be split in 2 groups, matched for age, weight, height and baseline carnosine concentrations in soleus and gastrocnemius medialis muscles. Fifteen of them will be supplemented with beta-alanine and creatine (Veg+Suppl) and the other 15 women will receive a placebo (Veg+Pla). A co-worker, not involved in the study design and analysis, will perform the randomisation and will prepare the containers with supplements. With regard to supplementation, the study is double-blind placebo-controlled. The lacto-ovo-vegetarian diet consists of vegetables, fruits, seeds, grains, meat substitutes, eggs and dairy products and the exclusion of meat, poultry and fish. Subjects will complete a 3 day food diary at the start and after 3 months and will receive nutritional advice by a dietician during the study to prevent deficiencies in macronutrients and micronutrients. Furthermore, vegetarian recipes will be provided by email to support the subjects in their vegetarian diet.
The supplementation protocol includes simultaneously daily oral administration of creatine monohydrate (Creapure®, AlzChem AG, Germany) and slow-release beta-alanine (Carnosyn®, Natural Alternatives International, San Marcos, USA) or a placebo (maltodextrin, Natural spices, France). The supplements are considered as safe and efficacious. The Veg+Suppl group ingests 1 g of creatine monohydrate (2 capsules of 500 mg) and 0.8 g of beta-alanine (1 Carnosyn® tablet) each day during the intervention period. The Veg+Pla group will be supplemented with an identical number of capsules and tablets of maltodextrin. All subjects are asked not to take any other supplements than those provided by the current study. Compliance will be checked by asking the subjects to return the containers and counting the pills that are left. The control group, who will remain on an omnivorous diet, will not receive any supplements.
Before (0M), after 3 (3M) and 6 months (6M), subjects will perform an incremental cycling test, a fasted venous blood sample and 24hr urine will be collected, a muscle biopsy of the vastus lateralis muscle will be taken and muscle carnosine content will be determined by 1H-MRS.
A two-way analysis of variance (ANOVA) will be used to evaluate plasma and urinary metabolite concentrations, muscle carnosine, muscle biopsy metabolite concentrations, time to exhaustion (TTE) and VO2max with 'group' (Veg+Suppl; Veg+Pla; control) as between-subject factor and 'time' (0M; 3M; 6M) as within-subject factor (SPSS statistical software, SPSS Inc, Chicago, USA). For the analysis of capillary lactate and pH, measurements before and after the incremental cycling test were included as another within factor (start; end). In case of significance, analyses were repeated for each group separately and pairwise comparisons were used to compare the different time points. Values will be presented as mean ± SD and statistical significance threshold will be set at p ≤0.05.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Other names: lacto-ovo-vegetarian diet
1g creatine/day
pills
0.8g beta-alanine per day
Time frame: 6 months
Fasted venous plasma beta-alanine concentration (precursor for carnosine) at 0, 3 and 6 months of the intervention
Time frame: 6 months
Gastrocnemius carnosine concentration at 0, 3 and 6 months of the intervention
Time frame: 6 months
Soleus carnosine concentration at 0, 3 and 6 months of the intervention
Time frame: 6 months
Plasma creatine concentration at 0, 3 and 6 months of the intervention
Time frame: 6 months
Plasma creatinine at 0, 3 and 6 months of the intervention
Time frame: 6 months
Plasma guanidinoacetate at 0, 3 and 6 months of the intervention
Time frame: 6 months
Urinary creatinine at 0, 3 and 6 months of the intervention
Time frame: 3 months
Muscle total creatine concentration in vastus lateralis muscle at 0 and 3 months of the intervention
Time frame: 6 months
plasma free carnitine concentration at 0, 3 and 6 months of the intervention
Time frame: 6 months
plasma acetylcarnitine concentration at 0, 3 and 6 months of the intervention
Time frame: 6 months
plasma total carnitine concentration (free + acetyl) at 0, 3 and 6 months of the intervention
Time frame: 3 months
muscle free carnitine concentration in vastus lateralis muscle at 0 and 3 months of the intervention
Time frame: 3 months
muscle acetylcarnitine concentration in vastus lateralis muscle at 0 and 3 months of the intervention
Time frame: 3 months
muscle total carnitine concentration (free + acetylcarnitine) in vastus lateralis muscle at 0 and 3 months of the intervention
Time frame: 6 months
Serum 25-Hydroxyvitamin D concentration at 0, 3 and 6 months of the intervention
Time frame: 6 months
urinary pi-methyl-histidine concentration at 0, 3 and 6 months of the intervention
Time frame: 6 months
urinary tau-methyl-histidine concentration at 0, 3 and 6 months of the intervention
Time frame: 6 months
urinary anserine concentration at 0, 3 and 6 months of the intervention
Time frame: 6 months
VO2max during incremental cycling test performed at 0, 3 and 6 months
Time frame: 6 months
Time to exhaustion during incremental cycling test performed at 0, 3 and 6 months
Time frame: 6 months
capillary lactate at the start and at the end of the incremental cycling test performed at 0, 3 and 6 months
Time frame: 6 months
capillary pH at the start and at the end of the incremental cycling test performed at 0, 3 and 6 months
University Ghent
Other
Effect of a 6-month Vegetarian Diet in Omnivorous Women on Body Creatine, Carnitine and Carnosine Stores
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03495986
Behavior, Central Nervous System Diseases
Miami, Florida, United States
View Trial DetailsNCT03796897
Behavior, Behavior, Animal
Hamilton, Ontario, Canada
View Trial DetailsNCT02772952
Behavior, Dietary Modification
Málaga, Spain
View Trial DetailsNCT03781011
Cardiovascular Diseases, Dietary Modification
Taipei, Taiwan
View Trial Details